BACKGROUND: Aberrant sialylation is a characteristic feature associated with cancer. The four types of mammalian sialidases identified to date have been shown to behave in different manners during carcinogenesis. While NEU1, NEU2 and NEU4 have been observed to oppose malignant phenotypes, the membrane-bound sialidase NEU3 was revealed to promote cancer progression. OBJECTIVES: With the aim of improving the knowledge about sialidases deregulation in various cancer types, we investigated the amount of NEU1, NEU3 and NEU4 transcripts in paired normal and tumor tissues from 170 patients with 11 cancer types. METHODS: mRNA was extracted from patients' tissue specimens and retrotranscribed into cDNA, which was quantified by Real-Time PCR. RESULTS: We found NEU1 and NEU3 to be up regulated, while NEU4 was down regulated in most cancer types. In particular, colorectal cancer tissues showed the highest increase in NEU3 expression. Both NEU1 and NEU3 showed a strong up-regulation in ovarian cancer. CONCLUSIONS: Our data show that human sialidases are expressed at different levels in healthy tissues and are strongly deregulated in tumors. Moreover, sialidases expression in our European cohort showed significant differences from Asian populations. Some of these peculiar features open potential applications of sialidases in cancer diagnosis and therapy.

Forcella, M., Mozzi, A., Stefanini, F., Riva, A., Epistolio, S., Molinari, F., et al. (2018). Deregulation of sialidases in human normal and tumor tissues. DISEASE MARKERS. SECTION A, CANCER BIOMARKERS, 21(3), 591-601 [10.3233/CBM-170548].

Deregulation of sialidases in human normal and tumor tissues

Forcella M.;Mozzi A.;Stefanini F. M.;Fusi P.;
2018

Abstract

BACKGROUND: Aberrant sialylation is a characteristic feature associated with cancer. The four types of mammalian sialidases identified to date have been shown to behave in different manners during carcinogenesis. While NEU1, NEU2 and NEU4 have been observed to oppose malignant phenotypes, the membrane-bound sialidase NEU3 was revealed to promote cancer progression. OBJECTIVES: With the aim of improving the knowledge about sialidases deregulation in various cancer types, we investigated the amount of NEU1, NEU3 and NEU4 transcripts in paired normal and tumor tissues from 170 patients with 11 cancer types. METHODS: mRNA was extracted from patients' tissue specimens and retrotranscribed into cDNA, which was quantified by Real-Time PCR. RESULTS: We found NEU1 and NEU3 to be up regulated, while NEU4 was down regulated in most cancer types. In particular, colorectal cancer tissues showed the highest increase in NEU3 expression. Both NEU1 and NEU3 showed a strong up-regulation in ovarian cancer. CONCLUSIONS: Our data show that human sialidases are expressed at different levels in healthy tissues and are strongly deregulated in tumors. Moreover, sialidases expression in our European cohort showed significant differences from Asian populations. Some of these peculiar features open potential applications of sialidases in cancer diagnosis and therapy.
Articolo in rivista - Articolo scientifico
Scientifica
cancer progression; diagnosis and therapy; sialidase expression; Sialome;
cancer progression; diagnosis and therapy; sialidase expression; Sialome
English
Forcella, M., Mozzi, A., Stefanini, F., Riva, A., Epistolio, S., Molinari, F., et al. (2018). Deregulation of sialidases in human normal and tumor tissues. DISEASE MARKERS. SECTION A, CANCER BIOMARKERS, 21(3), 591-601 [10.3233/CBM-170548].
Forcella, M; Mozzi, A; Stefanini, F; Riva, A; Epistolio, S; Molinari, F; Merlo, E; Monti, E; Fusi, P; Frattini, M
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10281/260577
Citazioni
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 10
Social impact